Biogen (BIIB) surged 6% on Wednesday following the release of its quarterly earnings, which exceeded analyst expectations despite a reduction in full-year guidance. The company reported total revenue of $2.48 billion for Q1 2026, up 2% year-over-year, surpassing the consensus estimate of $2.25 billion. Notably, Biogen’s attributable net income rose 19% to over $529 million, or $3.57 per share, beating the expected $2.95 per share. The strong performance was driven by significant sales growth in its “growth products” portfolio, particularly Leqembi, which saw a 74% increase in sales.
However, the guidance cut for adjusted net income to a range of $14.25 to $15.25 per share indicates potential headwinds, attributed to in-process research and development costs. Additionally, Biogen anticipates a mid-single-digit decline in revenue compared to 2025, excluding its upcoming acquisition of Apellis Pharmaceuticals for $5.6 billion.
For market professionals, the key takeaway is that while Biogen’s current momentum is promising, the lowered guidance and ongoing strategic shifts warrant close monitoring as it transitions from a focus on multiple sclerosis to broader therapeutic areas.
Source: fool.com